RxDoctor Payments Data

Carlos Guerra, MD

Infectious Disease · Fort Lauderdale, FLNPI 1992902753

Payments from drug & device makers

$4,962in general payments, 2019–2025

Across 154 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$1K
  • Gilead$943
  • Smith+Nephew$630
  • Johnson & Johnson$418
  • Viiv Healthcare Company$400
  • Organogenesis Inc.$380
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,83497%
  • Education$1283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,962 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$190,020
Medicare patients
404
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala246$1,033,872
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf106$507,931
GenvoyaElviteg/Cob/Emtri/Tenof Alafen111$458,185
TivicayDolutegravir Sodium100$244,129
DescovyEmtricitabine/Tenofov Alafenam81$209,172
TriumeqAbacavir/Dolutegravir/Lamivudi45$173,479
PrezcobixDarunavir/Cobicistat34$103,195
OdefseyEmtricitab/Rilpiviri/Tenof Ala19$96,869
JulucaDolutegravir/Rilpivirine25$94,199
ErtapenemErtapenem Sodium86$55,841
Daptomycin35$50,992
PifeltroDoravirine19$33,526
SantylCollagenase Clostridium Hist.47$22,311
EdurantRilpivirine Hcl11$16,653
Cefepime Hcl40$14,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$943$1,701,230438 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca$400$511,808170 claims
Janssen Products, LPSymtuza$1,125$507,931106 claims
Johnson & JohnsonPrezcobix$418$103,19534 claims
MerckPifeltro$77$33,52619 claims
Smith+NephewSantyl$630$22,31147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →